Targeting Cytosolic Phospholipase A2α for Novel Anti-​Inflammatory Agents

Soubhye, Jalal; Van Antwerpen, P.; Dufrasne, François

No full text

Book review (Scientific journals)

Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents

Soubhye, Jalal; Van Antwerpen, P.; Dufrasne, François

2018 • In Current Medicinal Chemistry, 25 (21), p. 2418-2447

Permalink
https://hdl.handle.net/20.500.12907/11053

PubMed
29345571

Files (0)Send to Details Statistics Bibliography Similar publications

Files

Full Text

No document available.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Soubhye, Jalal

Van Antwerpen, P.

Dufrasne, François ; Université de Mons > Faculté de Médecine et de Pharmacie > Service de Chimie thérapeutique et Pharmacognosie

Language :

English

Title :

Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents

Publication date :

31 December 2018

Journal title :

Current Medicinal Chemistry

ISSN :

0929-8673

Publisher :

Bentham Science Publishers, Schiphol, Netherlands

Volume :

Issue :

Pages :

2418-2447

Research unit :

M136 - Chimie thérapeutique et Pharmacognosie

Research institute :

R550 - Institut des Sciences et Technologies de la Santé

Available on ORBi UMONS :

since 15 January 2019

Statistics

Number of views

16 (0 by UMONS)

Number of downloads

0 (0 by UMONS)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Whicher, J.; Chambers, R. Mechanisms in chronic inflammation. Immunol. Today, 1984, 5(1), 3-4.
Kumar, R.; Clermont, G.; Vodovotz, Y.; Chow, C.C. The dynamics of acute inflammation. J. Theor. Biol., 2004, 230(2), 145-155.
Agita, A.; Alsagaff, M.T. Inflammation, immunity, and hypertension. Acta Med. Indones., 2017, 49(2), 158-165.
Basil, M.C.; Levy, B.D. Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation. Nat. Rev. Immunol., 2016, 16(1), 51-67.
Vaporciyan, A.A.; DeLisser, H.M.; Yan, H.C.; Mendiguren, I.I.; Thom, S.R.; Jones, M.L.; Ward, P.A.; Albelda, S.M. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science, 1993, 262(5139), 1580-1582.
Cotran, R.S.; Kumar, V.; Collins, T.; Robbins, S.L. Robbins pathologic basis of disease, 6th ed.; Saunders: Philadelphia, 1999.
Barnig, C.; Cernadas, M.; Dutile, S.; Liu, X.; Perrella, M.A.; Kazani, S.; Wechsler, M.E.; Israel, E.; Levy, B.D. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci. Transl. Med., 2013, 5(174), 174-26.
Bozinovski, S.; Uddin, M.; Vlahos, R.; Thompson, M.; McQualter, J.L.; Merritt, A-S.; Wark, P.A.B.; Hutchinson, A.; Irving, L.B.; Levy, B.D.; Anderson, G.P. Serum amyloid A opposes lipoxin A4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc. Natl. Acad. Sci. USA, 2012, 109(3), 935-940.
Levy, B.D.; Clish, C.B.; Schmidt, B.; Gronert, K.; Serhan, C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol., 2001, 2(7), 612-619.
Dufton, N.; Hannon, R.; Brancaleone, V.; Dalli, J.; Patel, H. B.; Gray, M.; D’Acquisto, F.; Buckingham, J. C.; Perretti, M.; Flower, R. J. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J. Immunol. Baltim., 2010, 184(5), 2611-2619.
Haworth, O.; Cernadas, M.; Levy, B. D. NK cells are effectors for resolvin E1 in the timely resolution of Allergic Airway Inflammation. J. Immunol., 2011, 186(11), 6129-6135.
Schwab, J.M.; Chiang, N.; Arita, M.; Serhan, C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature, 2007, 447(7146), 869-874.
Nordgren, T.M.; Heires, A.J.; Wyatt, T.A.; Poole, J.A.; LeVan, T.D.; Cerutis, D.R.; Romberger, D.J. Maresin-1 reduces the pro-inflammatory response of bronchial epithelial cells to organic dust. Respir. Res., 2013, 14, 51.
Libby, P. Inflammation in atherosclerosis. Nature, 2002, 420(6917), 868-874.
Majithia, V.; Geraci, S.A. Rheumatoid arthritis: Diagnosis and management. Am. J. Med., 2007, 120(11), 936-939.
Oldroyd, A.; Lilleker, J.; Chinoy, H. Idiopathic inflammatory myopathies -a guide to subtypes, diagnostic approach and treatment. Clin. Med. (Lond.), 2017, 17(4), 322-328.
Couser, W.G. Glomerulonephritis. Lancet, 1999, 353(9163), 1509-1515.
Steiman, A.J.; Pope, J.E.; Thiessen-Philbrook, H.; Li, L.; Barnabe, C.; Kalache, F.; Kung, T.; Bessette, L.; Flanagan, C.; Haraoui, B.; Hochman, J.; Leclercq, S.; Mosher, D.; Thorne, C.; Bykerk, V. Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. Rheumatol. Int., 2013, 33(5), 1105-1120.
Foye’s Principles of Medicinal Chemistry, 6th ed.; Foye, W. O., Lemke, T. L., Williams, D. A., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2008.
Feldmann, M.; Maini, R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med., 2003, 9(10), 1245-1250.
Present, D.H.; Rutgeerts, P.; Targan, S.; Hanauer, S.B.; Mayer, L.; van Hogezand, R.A.; Podolsky, D.K.; Sands, B.E.; Braakman, T.; DeWoody, K.L.; Schaible, T.F.; van Deventer, S.J. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med., 1999, 340(18), 1398-1405.
Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; Kastelein, J.J.P.; Cornel, J.H.; Pais, P.; Pella, D.; Genest, J.; Cifkova, R.; Lorenzatti, A.; Forster, T.; Kobalava, Z.; Vida-Simiti, L.; Flather, M.; Shimokawa, H.; Ogawa, H.; Dellborg, M.; Rossi, P.R.F.; Troquay, R.P.T.; Libby, P.; Glynn, R.J. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med., 2017, 377(12), 1119-1131.
Buchman, A.L. Side effects of corticosteroid therapy. J. Clin. Gastroenterol., 2001, 33(4), 289-294.
Patel, H.B.; Kornerup, K.N.; Sampaio, A.L.F.; D’Acquisto, F.; Seed, M.P.; Girol, A.P.; Gray, M.; Pitzalis, C.; Oliani, S.M.; Perretti, M. The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis. Ann. Rheum. Dis., 2012, 71(11), 1872-1880.
Parente, L.; Solito, E. Annexin 1: more than an antiphospholipase protein. Inflamm. Res., 2004, 53(4), 125-132.
Vane, J. R.; Botting, R. M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am. J. Med., 1998, 104(3A) 2S–8S; discussion 21S–22S.
Steinbach, G.; Lynch, P.M.; Phillips, R.K.S.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; Su, L-K.; Levin, B.; Godio, L.; Patterson, S.; Rodriguez-Bigas, M.A.; Jester, S.L.; King, K.L.; Schumacher, M.; Abbruzzese, J.; DuBois, R.N.; Hittelman, W.N.; Zimmerman, S.; Sherman, J.W.; Kelloff, G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 2000, 342(26), 1946-1952.
Bonventre, J. Cytosolic phospholipase A2α reigns supreme in arthritis and bone resorption. Trends Immunol., 2004, 25(3), 116-119.
Dennis, E.A. Introduction to thematic review series: Phospholipases: Central role in lipid signaling and disease. J. Lipid Res., 2015, 56(7), 1245-1247.
Dennis, E.A. Diversity of group types, regulation, and function of phospholipase A2. J. Biol. Chem., 1994, 269(18), 13057-13060.
Leslie, C.C. Cytosolic phospholipase A4: physiological function and role in disease. J. Lipid Res., 2015, 56(8), 1386-1402.
Lambeau, G.; Gelb, M.H. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu. Rev. Biochem., 2008, 77, 495-520.
Gijón, M.A.; Spencer, D.M.; Siddiqi, A.R.; Bonventre, J.V.; Leslie, C.C. Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that Do and Do not mobilize calcium. Novel role of mitogenactivated protein kinase pathways in cytosolic phospholipase A2 regulation. J. Biol. Chem., 2000, 275(26), 20146-20156.
Dennis, E.A.; Cao, J.; Hsu, Y-H.; Magrioti, V.; Kokotos, G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem. Rev., 2011, 111(10), 6130-6185.
Stafforini, D.M. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc. Drugs Ther., 2009, 23(1), 73-83.
Hiraoka, M.; Abe, A.; Lu, Y.; Yang, K.; Han, X.; Gross, R.W.; Shayman, J.A. Lysosomal phospholipase A2 and phospholipidosis. Mol. Cell. Biol., 2006, 26(16), 6139-6148.
Shayman, J.A.; Kelly, R.; Kollmeyer, J.; He, Y.; Abe, A. Group XV phospholipase A2, a lysosomal phospholipase A2. Prog. Lipid Res., 2011, 50(1), 1-13.
Hajnal, A.; Klemenz, R.; Schäfer, R. Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts. Oncogene, 1994, 9(2), 479-490.
Clark, J.D.; Schievella, A.R.; Nalefski, E.A.; Lin, L.L. Cytosolic phospholipase A2. J. Lipid Mediat. Cell Signal., 1995, 12(2-3), 83-117.
Ohto, T.; Uozumi, N.; Hirabayashi, T.; Shimizu, T. Identification of novel cytosolic phospholipase A(2)s, murine cPLA(2)delta, epsilon, and zeta, which form a gene cluster with cPLA(2)beta. J. Biol. Chem., 2005, 280(26), 24576-24583.
Ha, K.D.; Clarke, B.A.; Brown, W.J. Regulation of the Golgi complex by phospholipid remodeling enzymes. Biochim. Biophys. Acta, 2012, 1821(8), 1078-1088.
Alonso, F.; Henson, P.M.; Leslie, C.C. A cytosolic phospholipase in human neutrophils that hydrolyzes arachidonoyl-containing phosphatidylcholine. Biochim. Biophys. Acta, 1986, 878(2), 273-280.
Kramer, R.M.; Checani, G.C.; Deykin, A.; Pritzker, C.R.; Deykin, D. Solubilization and properties of Ca2+-dependent human platelet phospholipase A2. Biochim. Biophys. Acta, 1986, 878(3), 394-403.
Tay, A.; Simon, J.S.; Squire, J.; Hamel, K.; Jacob, H.J.; Skorecki, K. Cytosolic phospholipase A2 gene in human and rat: Chromosomal localization and polymorphic markers. Genomics, 1995, 26(1), 138-141.
Dessen, A.; Tang, J.; Schmidt, H.; Stahl, M.; Clark, J.D.; Seehra, J.; Somers, W.S. Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. Cell, 1999, 97(3), 349-360.
Xu, G-Y.; McDonagh, T.; Yu, H-A.; Nalefski, E.A.; Clark, J.D.; Cumming, D.A. Solution Structure and Membrane Interactions of the C2 Domain of Cytosolic Phospholipase A 2 1 1 Edited by J. Karn. J. Mol. Biol., 1998, 280(3), 485-500.
Lin, L.L.; Wartmann, M.; Lin, A.Y.; Knopf, J.L.; Seth, A.; Davis, R.J. cPLA2 is phosphorylated and activated by MAP kinase. Cell, 1993, 72(2), 269-278.
Nakamura, H.; Hirabayashi, T.; Shimizu, M.; Murayama, T. Ceramide-1-phosphate activates cytosolic phospholipase A2alpha directly and by PKC pathway. Biochem. Pharmacol., 2006, 71(6), 850-857.
Leslie, C.C.; Gangelhoff, T.A.; Gelb, M.H. Localization and function of cytosolic phospholipase A2α at the Golgi. Biochimie, 2010, 92(6), 620-626.
Lee, C.-W.; Lin, C.-C.; Lee, I.-T.; Lee, H.-C.; Yang, C.-M. Activation and induction of cytosolic phospholipase A2 by TNF-α mediated through Nox2, MAPKs, NF-κB, and p300 in human tracheal smooth muscle cells. J. Cell. Physiol., 2011, 226(8), 2103-2114.
Heasley, L.E.; Thaler, S.; Nicks, M.; Price, B.; Skorecki, K.; Nemenoff, R.A. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J. Biol. Chem., 1997, 272(23), 14501-14504.
Bickford, J.S.; Beachy, D.E.; Newsom, K.J.; Barilovits, S.J.; Herlihy, J-D.H.; Qiu, X.; Walters, J.N.; Li, N.; Nick, H.S. A distal enhancer controls cytokine-dependent human cPLA2α gene expression. J. Lipid Res., 2013, 54(7), 1915-1926.
Dolan-O’Keefe, M.; Chow, V.; Monnier, J.; Visner, G.A.; Nick, H.S. Transcriptional regulation and structural organization of the human cytosolic phospholipase A(2) gene. Am. J. Physiol. Lung Cell. Mol. Physiol., 2000, 278(4), L649-L657.
Sun, K.; Ma, R.; Cui, X.; Campos, B.; Webster, R.; Brockman, D.; Myatt, L. Glucocorticoids induce cytosolic phospholipase A2 and prostaglandin H synthase type 2 but not microsomal prostaglandin E synthase (PGES) and cytosolic PGES expression in cultured primary human amnion cells. J. Clin. Endocrinol. Metab., 2003, 88(11), 5564-5571.
Nalefski, E.A.; Wisner, M.A.; Chen, J.Z.; Sprang, S.R.; Fukuda, M.; Mikoshiba, K.; Falke, J.J. C2 domains from different Ca2+ signaling pathways display functional and mechanistic diversity. Biochemistry, 2001, 40(10), 3089-3100.
Davletov, B.; Perisic, O.; Williams, R.L. Calciumdependent membrane penetration is a hallmark of the C2 domain of cytosolic phospholipase A2 whereas the C2A domain of synaptotagmin binds membranes electrostatically. J. Biol. Chem., 1998, 273(30), 19093-19096.
Schievella, A.R.; Regier, M.K.; Smith, W.L.; Lin, L.-L. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J. Biol. Chem., 1995, 270(51), 30749-30754.
Evans, J.H.; Spencer, D.M.; Zweifach, A.; Leslie, C.C. Intracellular calcium signals regulating cytosolic phospholipase A2 translocation to internal membranes. J. Biol. Chem., 2001, 276(32), 30150-30160.
Hirabayashi, T.; Kume, K.; Hirose, K.; Yokomizo, T.; Iino, M.; Itoh, H.; Shimizu, T. Critical duration of intracellular Ca2+ response required for continuous translocation and activation of cytosolic phospholipase A2. J. Biol. Chem., 1999, 274(8), 5163-5169.
Tucker, D.E.; Ghosh, M.; Ghomashchi, F.; Loper, R.; Suram, S.; John, B.S.; Girotti, M.; Bollinger, J.G.; Gelb, M.H.; Leslie, C.C. Role of phosphorylation and basic residues in the catalytic domain of cytosolic phospholipase A2alpha in regulating interfacial kinetics and binding and cellular function. J. Biol. Chem., 2009, 284(14), 9596-9611.
Bayburt, T.; Gelb, M.H. Interfacial catalysis by human 85 kDa cytosolic phospholipase A2 on anionic vesicles in the scooting mode. Biochemistry, 1997, 36(11), 3216-3231.
Kramer, R.M.; Roberts, E.F.; Um, S.L.; Börsch-Haubold, A.G.; Watson, S.P.; Fisher, M.J.; Jakubowski, J.A. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J. Biol. Chem., 1996, 271(44), 27723-27729.
Casas, J.; Meana, C.; Esquinas, E.; Valdearcos, M.; Pindado, J.; Balsinde, J.; Balboa, M. A. Requirement of JNK mediated phosphorylation for translocation of group IVA phospholipase A2 to phagosomes in human macro-phages. J. Immunol. Baltim. Md 1950, 2009, 183(4), 2767-2774.
Gubern, A.; Barceló-Torns, M.; Barneda, D.; López, J.M.; Masgrau, R.; Picatoste, F.; Chalfant, C.E.; Balsinde, J.; Balboa, M.A.; Claro, E. JNK and ceramide kinase govern the biogenesis of lipid droplets through activation of group IVA phospholipase A2. J. Biol. Chem., 2009, 284(47), 32359-32369.
Pavicevic, Z.; Leslie, C.C.; Malik, K.U. cPLA2 phosphorylation at serine-515 and serine-505 is required for arachidonic acid release in vascular smooth muscle cells. J. Lipid Res., 2008, 49(4), 724-737.
Pettus, B.J.; Bielawska, A.; Spiegel, S.; Roddy, P.; Hannun, Y.A.; Chalfant, C.E. Ceramide kinase mediates cytokineand calcium ionophore-induced arachidonic acid release. J. Biol. Chem., 2003, 278(40), 38206-38213.
Lamour, N.F.; Stahelin, R.V.; Wijesinghe, D.S.; Maceyka, M.; Wang, E.; Allegood, J.C.; Merrill, A.H., Jr; Cho, W.; Chalfant, C.E. Ceramide kinase uses ceramide provided by ceramide transport protein: localization to organelles of eicosanoid synthesis. J. Lipid Res., 2007, 48(6), 1293-1304.
Hefner, Y.; Borsch-Haubold, A.G.; Murakami, M.; Wilde, J.I.; Pasquet, S.; Schieltz, D.; Ghomashchi, F.; Yates, J.R., III; Armstrong, C.G.; Paterson, A.; Cohen, P.; Fukunaga, R.; Hunter, T.; Kudo, I.; Watson, S.P.; Gelb, M.H. Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J. Biol. Chem., 2000, 275(48), 37542-37551.
Börsch-Haubold, A.G.; Bartoli, F.; Asselin, J.; Dudler, T.; Kramer, R.M.; Apitz-Castro, R.; Watson, S.P.; Gelb, M.H. Identification of the phosphorylation sites of cytosolic phospholipase A2 in agonist-stimulated human platelets and HeLa cells. J. Biol. Chem., 1998, 273(8), 4449-4458.
Tian, W.; Wijewickrama, G.T.; Kim, J.H.; Das, S.; Tun, M.P.; Gokhale, N.; Jung, J.W.; Kim, K.P.; Cho, W. Mechanism of regulation of group IVA phospholipase A2 activity by Ser727 phosphorylation. J. Biol. Chem., 2008, 283(7), 3960-3971.
Nalefski, E.A.; Slazas, M.M.; Falke, J.J. Ca2+-signaling cycle of a membrane-docking C2 domain. Biochemistry, 1997, 36(40), 12011-12018.
Nalefski, E.A.; Falke, J.J. Cation charge and size selectivity of the C2 domain of cytosolic phospholipase A(2). Biochemistry, 2002, 41(4), 1109-1122.
Ball, A.; Nielsen, R.; Gelb, M.H.; Robinson, B.H. Interfacial membrane docking of cytosolic phospholipase A2 C2 domain using electrostatic potential-modulated spin relaxation magnetic resonance. Proc. Natl. Acad. Sci. USA, 1999, 96(12), 6637-6642.
Perisic, O.; Paterson, H.F.; Mosedale, G.; Lara-González, S.; Williams, R.L. Mapping the phospholipid-binding surface and translocation determinants of the C2 domain from cytosolic phospholipase A2. J. Biol. Chem., 1999, 274(21), 14979-14987.
Sundarraj, S.; Kannan, S.; Thangam, R.; Gunasekaran, P. Effects of the inhibition of cytosolic phospholipase A(2)α in non-small cell lung cancer cells. J. Cancer Res. Clin. Oncol., 2012, 138(5), 827-835.
Anwar, K.; Voloshyna, I.; Littlefield, M.J.; Carsons, S.E.; Wirkowski, P.A.; Jaber, N.L.; Sohn, A.; Eapen, S.; Reiss, A.B. COX-2 inhibition and inhibition of cytosolic phospholipase A2 increase CD36 expression and foam cell formation in THP-1 cells. Lipids, 2011, 46(2), 131-142.
Hewson, C.A.; Patel, S.; Calzetta, L.; Campwala, H.; Havard, S.; Luscombe, E.; Clarke, P.A.; Peachell, P.T.; Matera, M.G.; Cazzola, M.; Page, C.; Abraham, W.M.; Williams, C.M.; Clark, J.D.; Liu, W.L.; Clarke, N.P.; Yeadon, M. Preclinical evaluation of an inhibitor of cytosolic phospholipase A2α for the treatment of asthma. J. Pharmacol. Exp. Ther., 2012, 340(3), 656-665.
Clark, J.D.; Williams, C.M.M. Utility of Cytosolic Phospholipase A2α (cPLA2α)Inhibitors in the Treatment of Asthma. In Progress in Respiratory Research; Hansel, T. T., Barnes, P. J., Eds.; KARGER: Basel, 2010; Vol. 39, pp 207–212.
Lehr, M. Inhibitors of cytosolic phospholipase A2α(cPLA2α) as potential anti-inflammatory drugs. Antiinflamm. Antiallergy Agents Med. Chem., 2006, 5(2), 149-161.
Bonventre, J.V.; Huang, Z.; Taheri, M.R.; O’Leary, E.; Li, E.; Moskowitz, M.A.; Sapirstein, A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature, 1997, 390(6660), 622-625.
Uozumi, N.; Kume, K.; Nagase, T.; Nakatani, N.; Ishii, S.; Tashiro, F.; Komagata, Y.; Maki, K.; Ikuta, K.; Ouchi, Y.; Miyazaki, J.; Shimizu, T. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature, 1997, 390(6660), 618-622.
Peng, S-Y.; Liu, Y.; Bao, X.H.; Wang, L.; Zhang, F.Y.; Wang, F.; Wang, W.J. Inhibition of 5-lipoxygenase and cyclooxygenase-2 pathways by pain-relieving plaster in macrophages. Pharm. Biol., 2011, 49(7), 716-726.
Klegeris, A.; McGeer, P.L. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol. Aging, 2002, 23(5), 787-794.
Smith, W.L.; Urade, Y.; Jakobsson, P-J. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem. Rev., 2011, 111(10), 5821-5865.
Yuan, C.; Smith, W.L.A. A cyclooxygenase-2-dependent prostaglandin E2 biosynthetic system in the Golgi apparatus. J. Biol. Chem., 2015, 290(9), 5606-5620.
Grewal, S.; Ponnambalam, S.; Walker, J.H. Association of cPLA2-alpha and COX-1 with the Golgi apparatus of A549 human lung epithelial cells. J. Cell Sci., 2003, 116(Pt 11), 2303-2310.
Ricciotti, E.; FitzGerald, G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol., 2011, 31(5), 986-1000.
Chen, X-S.; Funk, C.D. The N-terminal “β-barrel” domain of 5-lipoxygenase is essential for nuclear membrane translocation. J. Biol. Chem., 2001, 276(1), 811-818.
Kulkarni, S.; Das, S.; Funk, C.D.; Murray, D.; Cho, W. Molecular basis of the specific subcellular localization of the C2-like domain of 5-lipoxygenase. J. Biol. Chem., 2002, 277(15), 13167-13174.
Evans, J.F.; Ferguson, A.D.; Mosley, R.T.; Hutchinson, J.H. What’s all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol. Sci., 2008, 29(2), 72-78.
Mandal, A.K.; Jones, P.B.; Bair, A.M.; Christmas, P.; Miller, D.; Yamin, T.T.; Wisniewski, D.; Menke, J.; Evans, J.F.; Hyman, B.T.; Bacskai, B.; Chen, M.; Lee, D.M.; Nikolic, B.; Soberman, R.J. The nuclear membrane organization of leukotriene synthesis. Proc. Natl. Acad. Sci. USA, 2008, 105(51), 20434-20439.
Rudberg, P.C.; Tholander, F.; Andberg, M.; Thunnissen, M.M.G.M.; Haeggström, J.Z. Leukotriene A4 hydrolase: identification of a common carboxylate recognition site for the epoxide hydrolase and aminopeptidase substrates. J. Biol. Chem., 2004, 279(26), 27376-27382.
Legler, D.F.; Bruckner, M.; Uetz-von Allmen, E.; Krause, P. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol., 2010, 42(2), 198-201.
Li, M.; Thompson, D.D.; Paralkar, V.M. Prostaglandin E(2) receptors in bone formation. Int. Orthop., 2007, 31(6), 767-772.
Fortier, M.A.; Krishnaswamy, K.; Danyod, G.; Boucher-Kovalik, S.; Chapdalaine, P. A postgenomic integrated view of prostaglandins in reproduction: implications for other body systems. J. Physiol. Pharmacol., 2008, 59(Suppl. 1), 65-89.
Dey, I.; Lejeune, M.; Chadee, K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br. J. Pharmacol., 2006, 149(6), 611-623.
Ii, H.; Hatakeyama, S.; Tsutsumi, K.; Sato, T.; Akiba, S. Group IVA phospholipase A2 is associated with the storage of lipids in adipose tissue and liver. Prostaglandins Other Lipid Mediat., 2008, 86(1-4), 12-17.
Nissim, S.; Sherwood, R.I.; Wucherpfennig, J.; Saunders, D.; Harris, J.M.; Esain, V.; Carroll, K.J.; Frechette, G.M.; Kim, A.J.; Hwang, K.L.; Cutting, C.C.; Elledge, S.; North, T.E.; Goessling, W. Prostaglandin E2 regulates liver versus pancreas cell-fate decisions and endodermal outgrowth. Dev. Cell, 2014, 28(4), 423-437.
Rincón-Sánchez, A.R.; Covarrubias, A.; Rivas-Estilla, A.M.; Pedraza-Chaverrí, J.; Cruz, C.; Islas-Carbajal, M.C.; Panduro, A.; Estanes, A.; Armendáriz-Borunda, J. PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damage. Exp. Toxicol. Pathol., 2005, 56(4-5), 291-303.
Fabre, J-E.; Nguyen, M.; Athirakul, K.; Coggins, K.; McNeish, J.D.; Austin, S.; Parise, L.K.; FitzGerald, G.A.; Coffman, T.M.; Koller, B.H. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J. Clin. Invest., 2001, 107(5), 603-610.
Hartney, J.M.; Coggins, K.G.; Tilley, S.L.; Jania, L.A.; Lovgren, A.K.; Audoly, L.P.; Koller, B.H. Prostaglandin E2 protects lower airways against bronchoconstriction. Am. J. Physiol. Lung Cell. Mol. Physiol., 2006, 290(1), L105-L113.
Säfholm, J.; Manson, M.L.; Bood, J.; Delin, I.; Orre, A-C.; Bergman, P.; Al-Ameri, M.; Dahlén, S-E.; Adner, M. Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor. J. Allergy Clin. Immunol., 2015, 136(5), 1232-9.e1.
Yao, C.; Sakata, D.; Esaki, Y.; Li, Y.; Matsuoka, T.; Kuroiwa, K.; Sugimoto, Y.; Narumiya, S. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med., 2009, 15(6), 633-640.
Legler, D. F.; Krause, P.; Scandella, E.; Singer, E.; Groettrup, M. Prostaglandin E2 Is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J. Immu-nol. Baltim. Md 1950, 2006, 176(2), 966-973.
Rappaport, R.S.; Dodge, G.R.; Prostaglandin, E. Prostaglandin E inhibits the production of human interleukin 2. J. Exp. Med., 1982, 155(3), 943-948.
Zitnik, R.J.; Zheng, T.; Elias, J.A. cAMP inhibition of interleukin-1-induced interleukin-6 production by human lung fibroblasts. Am. J. Physiol., 1993, 264(3 Pt 1), L253
Shmelzer, Z.; Haddad, N.; Admon, E.; Pessach, I.; Leto, T.L.; Eitan-Hazan, Z.; Hershfinkel, M.; Levy, R. Unique targeting of cytosolic phospholipase A2 to plasma membranes mediated by the NADPH oxidase in phagocytes. J. Cell Biol., 2003, 162(4), 683-692.
Malada-Edelstein, Y.F.; Hadad, N.; Levy, R. Regulatory role of cytosolic phospholipase A2alpha in the induction of CD40 in microglia. J. Neuroinflammation, 2017, 14(1), 33. doi: 10.1186/s12974-017-0811-z.
Levy, R. The role of cytosolic phospholipase A2-alfa in regulation of phagocytic functions. Biochim. Biophys. Acta, 2006, 1761(11), 1323-1334.
Vilella, F.; Ramirez, L.; Berlanga, O.; Martínez, S.; Alamá, P.; Meseguer, M.; Pellicer, A.; Simón, C. PGE2 and PGF2α concentrations in human endometrial fluid as biomarkers for embryonic implantation. J. Clin. Endocrinol. Metab., 2013, 98(10), 4123-4132.
Takahashi, Y.; Tokuoka, S.; Masuda, T.; Hirano, Y.; Nagao, M.; Tanaka, H.; Inagaki, N.; Narumiya, S.; Nagai, H. Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. Br. J. Pharmacol., 2002, 137(3), 315-322.
Kelton, J.G.; Blajchman, M.A. Prostaglandin I2 (prostacyclin). Can. Med. Assoc. J., 1980, 122(2), 175-179.
Urade, Y.; Hayaishi, O. Prostaglandin D2 and sleep/wake regulation. Sleep Med. Rev., 2011, 15(6), 411-418.
O’Sullivan, S. On the role of PGD2 metabolites as markers of mast cell activation in asthma. Acta Physiol. Scand. Suppl., 1999, 644, 1-74.
Farhat, A.; Philibert, P.; Sultan, C.; Poulat, F.; Boizet-Bonhoure, B. Hematopoietic-Prostaglandin D2 synthase through PGD2 production is involved in the adult ovarian physiology. J. Ovarian Res., 2011, 4(1), 3.
Matsuoka, T.; Hirata, M.; Tanaka, H.; Takahashi, Y.; Murata, T.; Kabashima, K.; Sugimoto, Y.; Kobayashi, T.; Ushikubi, F.; Aze, Y.; Eguchi, N.; Urade, Y.; Yoshida, N.; Kimura, K.; Mizoguchi, A.; Honda, Y.; Nagai, H.; Narumiya, S. Prostaglandin D2 as a mediator of allergic asthma. Science, 2000, 287(5460), 2013-2017.
Sugimoto, Y.; Yamasaki, A.; Segi, E.; Tsuboi, K.; Aze, Y.; Nishimura, T.; Oida, H.; Yoshida, N.; Tanaka, T.; Katsuyama, M.; Hasumoto, K.; Murata, T.; Hirata, M.; Ushikubi, F.; Negishi, M.; Ichikawa, A.; Narumiya, S. Failure of parturition in mice lacking the prostaglandin F receptor. Science, 1997, 277(5326), 681-683.
Breyer, M.D.; Breyer, R.M.G. G protein-coupled prostanoid receptors and the kidney. Annu. Rev. Physiol., 2001, 63(1), 579-605.
Nakahata, K.; Kinoshita, H.; Tokinaga, Y.; Ishida, Y.; Kimoto, Y.; Dojo, M.; Mizumoto, K.; Ogawa, K.; Hatano, Y. Vasodilation mediated by inward rectifier K+ channels in cerebral microvessels of hypertensive and normotensive rats. Anesth. Analg., 2006, 102(2), 571-576.
Nakahata, N. Thromboxane A2: Physiology/ pathophysiology, cellular signal transduction and pharmacology. Pharmacol. Ther., 2008, 118(1), 18-35.
Minami, K.; Kamei, C. A chronic model for evaluating the itching associated with allergic conjunctivitis in rats. Int. Immunopharmacol., 2004, 4(1), 101-108.
Crooks, S.W.; Stockley, R.A. Leukotriene B4. Int. J. Biochem. Cell Biol., 1998, 30(2), 173-178.
Haeggström, J.Z.; Funk, C.D. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem. Rev., 2011, 111(10), 5866-5898.
Cikler, E.; Ersoy, Y.; Cetinel, S.; Ercan, F. The leukotriene d4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress. Acta Histochem., 2009, 111(2), 112-118.
Claesson, H-E. On the biosynthesis and biological role of eoxins and 15-lipoxygenase-1 in airway inflammation and Hodgkin lymphoma. Prostaglandins Other Lipid Mediat., 2009, 89(3-4), 120-125.
Jiang, W.G.; Watkins, G.; Douglas-Jones, A.; Mansel, R.E. Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. Prostaglandins Leukot. Essent. Fatty Acids, 2006, 74(4), 235-245.
Shureiqi, I.; Wu, Y.; Chen, D.; Yang, X.L.; Guan, B.; Morris, J.S.; Yang, P.; Newman, R.A.; Broaddus, R.; Hamilton, S.R.; Lynch, P.; Levin, B.; Fischer, S.M.; Lippman, S.M. The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res., 2005, 65(24), 11486-11492.
Ivanov, I.; Kuhn, H.; Heydeck, D. Structural and functional biology of arachidonic acid 15-lipoxygenase-1 (ALOX15). Gene, 2015, 573(1), 1-32.
Faioni, E.M.; Razzari, C.; Zulueta, A.; Femia, E.A.; Fenu, L.; Trinchera, M.; Podda, G.M.; Pugliano, M.; Marongiu, F.; Cattaneo, M. Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency. Thromb. Haemost., 2014, 112(6), 1182-1189.
Adler, D.H.; Cogan, J.D.; Phillips, J.A., III; Schnetz-Boutaud, N.; Milne, G.L.; Iverson, T.; Stein, J.A.; Brenner, D.A.; Morrow, J.D.; Boutaud, O.; Oates, J.A. Inherited human cPLA(2α) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J. Clin. Invest., 2008, 118(6), 2121-2131.
Brooke, M.A.; Longhurst, H.J.; Plagnol, V.; Kirkby, N.S.; Mitchell, J.A.; Rüschendorf, F.; Warner, T.D.; Kelsell, D.P.; MacDonald, T.T. Cryptogenic multifocal ulcerating stenosing enteritis associated with homozygous deletion mutations in cytosolic phospholipase A2-α. Gut, 2014, 63(1), 96-104.
Sun, G.Y.; Chuang, D.Y.; Zong, Y.; Jiang, J.; Lee, J.C.M.; Gu, Z.; Simonyi, A. Role of cytosolic phospholipase A2 in oxidative and inflammatory signaling pathways in different cell types in the central nervous system. Mol. Neurobiol., 2014, 50(1), 6-14.
Tibes, U.; Vondran, A.; Rodewald, E.; Friebe, W.G.; Schäfer, W.; Scheuer, W. Inhibition of allergic and nonallergic inflammation by phospholipase A2 inhibitors. Int. Arch. Allergy Immunol., 1995, 107(1-3), 432-434.
Oestvang, J.; Johansen, B. PhospholipaseA2: A key regulator of inflammatory signalling and a connector to fibrosis development in atherosclerosis. Biochim. Biophys. Acta, 2006, 1761(11), 1309-1316.
Liu, N-K.; Deng, L-X.; Zhang, Y.P.; Lu, Q-B.; Wang, X-F.; Hu, J-G.; Oakes, E.; Bonventre, J.V.; Shields, C.B.; Xu, XM. Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury. Ann. Neurol., 2014, 75(5), 644-658.
López-Vales, R.; Ghasemlou, N.; Redensek, A.; Kerr, B.J.; Barbayianni, E.; Antonopoulou, G.; Baskakis, C.; Rathore, K.I.; Constantinou-Kokotou, V.; Stephens, D.; Shimizu, T.; Dennis, E.A.; Kokotos, G.; David, S. Phospholipase A2 superfamily members play divergent roles after spinal cord injury. FASEB J., 2011, 25(12), 4240-4252.
Watanabe, H.; Numata, K.; Ito, T.; Takagi, K.; Matsukawa, A. Innate immune response in Th1-and Th2-dominant mouse strains. Shock, 2004, 22(5), 460-466.
Sun, G.Y.; Shelat, P.B.; Jensen, M.B.; He, Y.; Sun, A.Y.; Simonyi, A. Phospholipases A2 and inflammatory responses in the central nervous system. Neuromol. Med., 2010, 12(2), 133-148.
Klivenyi, P.; Beal, M.F.; Ferrante, R.J.; Andreassen, O.A.; Wermer, M.; Chin, M.R.; Bonventre, J.V. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. J. Neurochem., 1998, 71(6), 2634-2637.
Sagy-Bross, C.; Kasianov, K.; Solomonov, Y.; Braiman, A.; Friedman, A.; Hadad, N.; Levy, R. The role of cytosolic phospholipase A2 α in amyloid precursor protein induction by amyloid beta1-42: Implication for neurodegeneration. J. Neurochem., 2015, 132(5), 559-571.
Montrose, D.C.; Kadaveru, K.; Ilsley, J.N.M.; Root, S.H.; Rajan, T.V.; Ramesh, M.; Nichols, F.C.; Liang, B.T.; Sonin, D.; Hand, A.R.; Zarini, S.; Murphy, R.C.; Belinsky, G.S.; Nakanishi, M.; Rosenberg, D.W. cPLA2 is protective against COX inhibitor-induced intestinal damage. Toxicol. Sci., 2010, 117(1), 122-132.
Montrose, D.C.; Nakanishi, M.; Murphy, R.C.; Zarini, S.; McAleer, J.P.; Vella, A.T.; Rosenberg, D.W. The role of PGE2 in intestinal inflammation and tumorigenesis. Prostaglandins Other Lipid Mediat., 2015, 116-117, 26-36.
Takaku, K.; Sonoshita, M.; Sasaki, N.; Uozumi, N.; Doi, Y.; Shimizu, T.; Taketo, M.M. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J. Biol. Chem., 2000, 275(44), 34013-34016.
Wang, D.; Dubois, R.N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene, 2010, 29(6), 781-788.
Wang, D.; DuBois, R.N. An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J., 2013, 19(6), 502-510.
Wang, D.; DuBois, R.N. The role of anti-inflammatory drugs in colorectal cancer. Annu. Rev. Med., 2013, 64, 131-144.
Oshima, M.; Dinchuk, J.E.; Kargman, S.L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J.M.; Evans, J.F.; Taketo, M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 1996, 87(5), 803-809.
Vassaux, G.; Gaillard, D.; Darimont, C.; Ailhaud, G.; Negrel, R. Differential response of preadipocytes and adipocytes to prostacyclin and prostaglandin E2: Physiological implications. Endocrinology, 1992, 131(5), 2393-2398.
Mazid, M.A.; Chowdhury, A.A.; Nagao, K.; Nishimura, K.; Jisaka, M.; Nagaya, T.; Yokota, K. Endogenous 15-deoxy-Δ(12,14)-prostaglandin J(2) synthesized by adipocytes during maturation phase contributes to upregulation of fat storage. FEBS Lett., 2006, 580(30), 6885-6890.
Enomoto, N.; Ikejima, K.; Yamashina, S.; Enomoto, A.; Nishiura, T.; Nishimura, T.; Brenner, D.A.; Schemmer, P.; Bradford, B.U.; Rivera, C.A.; Zhong, Z.; Thurman, R.G. Kupffer cell-derived prostaglandin E(2) is involved in alcohol-induced fat accumulation in rat liver. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 279(1), G100-G106.
Ii, H.; Hatakeyama, S.; Tsutsumi, K.; Sato, T.; Akiba, S. Group IVA phospholipase A2 is associated with the storage of lipids in adipose tissue and liver. Prostaglandins Other Lipid Mediat., 2008, 86(1-4), 12-17.
Ii, H.; Yokoyama, N.; Yoshida, S.; Tsutsumi, K.; Hatakeyama, S.; Sato, T.; Ishihara, K.; Akiba, S. Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A2-knockout mice. PLoS One, 2009, 4(12), e8089.
Ishihara, K.; Miyazaki, A.; Nabe, T.; Fushimi, H.; Iriyama, N.; Kanai, S.; Sato, T.; Uozumi, N.; Shimizu, T.; Akiba, S. Group IVA phospholipase A2 participates in the progression of hepatic fibrosis. FASEB J., 2012, 26(10), 4111-4121.
Yoshioka, W.; Kawaguchi, T.; Fujisawa, N.; Aida-Yasuoka, K.; Shimizu, T.; Matsumura, F.; Tohyama, C. Predominant role of cytosolic phospholipase A2α in dioxin-induced neonatal hydronephrosis in mice. Sci. Rep., 2014, 4. 4042. doi: 10.1038/srep04042
Nishimura, N.; Matsumura, F.; Vogel, C.F.A.; Nishimura, H.; Yonemoto, J.; Yoshioka, W.; Tohyama, C. Critical role of cyclooxygenase-2 activation in pathogenesis of hydronephrosis caused by lactational exposure of mice to dioxin. Toxicol. Appl. Pharmacol., 2008, 231(3), 374-383.
Kinehara, M.; Fukuda, I.; Yoshida, K.; Ashida, H. Highthroughput evaluation of aryl hydrocarbon receptor-binding sites selected via chromatin immunoprecipitation-based screening in Hepa-1c1c7 cells stimulated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Genes Genet. Syst., 2008, 83(6), 455-468.
Irvin, C.G.; Tu, Y.P.; Sheller, J.R.; Funk, C.D. 5-Lipoxygenase products are necessary for ovalbumininduced airway responsiveness in mice. Am. J. Physiol., 1997, 272(6 Pt 1), L1053-L1058.
Gavett, S.H.; Madison, S.L.; Chulada, P.C.; Scarborough, P.E.; Qu, W.; Boyle, J.E.; Tiano, H.F.; Lee, C.A.; Langenbach, R.; Roggli, V.L.; Zeldin, D.C. Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J. Clin. Invest., 1999, 104(6), 721-732.
Whalen, K.A.; Legault, H.; Hang, C.; Hill, A.; Kasaian, M.; Donaldson, D.; Bensch, G.W.; Bensch, G.; Baker, J.; Reddy, P.S.; Wood, N.; Ramarao, M.K.; Ellis, D.K.; Csimma, C.; McKee, C.; Clark, J.D.; Ryan, J.; Dorner, A.J.; O’Toole, M. In vitro allergen challenge of peripheral blood induces differential gene expression in mononuclear cells of asthmatic patients: inhibition of cytosolic phospholipase A2alpha overcomes the asthma-associated response. Clin. Exp. Allergy, 2008, 38(10), 1590-1605.
Selman, M.; King, T.E.; Pardo, A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med., 2001, 134(2), 136-151.
Nagase, T.; Uozumi, N.; Ishii, S.; Kume, K.; Izumi, T.; Ouchi, Y.; Shimizu, T. Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. Nat. Immunol., 2000, 1(1), 42-46.
Meyer, A.M.; Dwyer-Nield, L.D.; Hurteau, G.J.; Keith, R.L.; O’Leary, E.; You, M.; Bonventre, J.V.; Nemenoff, R.A.; Malkinson, A.M. Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis, 2004, 25(8), 1517-1524.
Marusic, S.; Leach, M.W.; Pelker, J.W.; Azoitei, M.L.; Uozumi, N.; Cui, J.; Shen, M.W.H.; DeClercq, C.M.; Miyashiro, J.S.; Carito, B.A.; Thakker, P.; Simmons, D.L.; Leonard, J.P.; Shimizu, T.; Clark, J.D. Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J. Exp. Med., 2005, 202(6), 841-851.
Martin, R.; McFarland, H.F. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci., 1995, 32(2), 121-182.
Griffiths, R.J.; Pettipher, E.R.; Koch, K.; Farrell, C.A.; Breslow, R.; Conklyn, M.J.; Smith, M.A.; Hackman, B.C.; Wimberly, D.J.; Milici, A.J. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc. Natl. Acad. Sci. USA, 1995, 92(2), 517-521.
Griffiths, R.J.; Smith, M.A.; Roach, M.L.; Stock, J.L.; Stam, E.J.; Milici, A.J.; Scampoli, D.N.; Eskra, J.D.; Byrum, R.S.; Koller, B.H.; McNeish, J.D. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating proteindeficient mice. J. Exp. Med., 1997, 185(6), 1123-1129.
Myers, L.K.; Kang, A.H.; Postlethwaite, A.E.; Rosloniec, E.F.; Morham, S.G.; Shlopov, B.V.; Goorha, S.; Ballou, L.R. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum., 2000, 43(12), 2687-2693.
Miyaura, C.; Inada, M.; Matsumoto, C.; Ohshiba, T.; Uozumi, N.; Shimizu, T.; Ito, A. An essential role of cytosolic phospholipase A2α in prostaglandin E2-mediated bone resorption associated with inflammation. J. Exp. Med., 2003, 197(10), 1303-1310.
Nakanishi, M.; Rosenberg, D.W. Roles of cPLA2alpha and arachidonic acid in cancer. Biochim. Biophys. Acta, 2006, 1761(11), 1335-1343.
Caiazza, F.; Harvey, B.J.; Thomas, W. Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth. Mol. Endocrinol., 2010, 24(5), 953-968.
Ilsley, J.N.M.; Nakanishi, M.; Flynn, C.; Belinsky, G.S.; De Guise, S.; Adib, J.N.; Dobrowsky, R.T.; Bonventre, J.V.; Rosenberg, D.W. Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res., 2005, 65(7), 2636-2643.
Meyer, A.M.; Dwyer-Nield, L.D.; Hurteau, G.J.; Keith, R.L.; O’Leary, E.; You, M.; Bonventre, J.V.; Nemenoff, R.A.; Malkinson, A.M. Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis, 2004, 25(8), 1517-1524.
Linkous, A.G.; Yazlovitskaya, E.M.; Hallahan, D.E. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J. Natl. Cancer Inst., 2010, 102(18), 1398-1412.
Ghomashchi, F.; Loo, R.; Balsinde, J.; Bartoli, F.; Apitz-Castro, R.; Clark, J.D.; Dennis, E.A.; Gelb, M.H. Trifluoromethyl ketones and methyl fluorophosphonates as inhibitors of group IV and VI phospholipases A(2): structure-function studies with vesicle, micelle, and membrane assays. Biochim. Biophys. Acta, 1999, 1420(1-2), 45-56.
Bayburt, T.; Yu, B-Z.; Street, I.; Ghomashchi, F.; Laliberté, F.; Perrier, H.; Wang, Z.; Homan, R.; Jain, M.K.; Gelb, M.H. Continuous, vesicle-based fluorimetric assays of 14-and 85-kDa phospholipases A2. Anal. Biochem., 1995, 232(1), 7-23.
Huang, Z.; Laliberté, F.; Tremblay, N.M.; Weech, P.K.; Street, I.P. A continuous fluorescence-based assay for the human high-molecular-weight cytosolic phospholipase A2. Anal. Biochem., 1994, 222(1), 110-115.
Ono, T.; Yamada, K.; Chikazawa, Y.; Ueno, M.; Nakamoto, S.; Okuno, T.; Seno, K. Characterization of a novel inhibitor of cytosolic phospholipase A2α, pyrrophenone. Biochem. J., 2002, 363(Pt 3), 727-735.
Schmitt, M.; Lehr, M. HPLC assay with UV spectrometric detection for the evaluation of inhibitors of cytosolic phospholipase A2. J. Pharm. Biomed. Anal., 2004, 35(1), 135-142.
Hanekamp, W.; Lehr, M. Determination of arachidonic acid by on-line solid-phase extraction HPLC with UV detection for screening of cytosolic phospholipase A2α inhibitors. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2012, 900, 79-84.
Reynolds, L.J.; Hughes, L.L.; Yu, L.; Dennis, E.A. 1-Hexadecyl-2-arachidonoylthio-2-deoxy-sn-glycero-3-phosphorylcholine as a substrate for the microtiterplate assay of human cytosolic phospholipase A2. Anal. Biochem., 1994, 217(1), 25-32.
Ramarao, M.K.; Shen, M.W.H.; Murphy, E.A.; Duan, W.; Zhao, Y.; McKew, J.; Lee, K.L.; Thakker, P.; Behnke, M.L.; Clark, J.D. Thermodynamic characterization of cytosolic phospholipase A2 alpha inhibitors. Anal. Biochem., 2008, 383(2), 217-225.
Seno, K.; Okuno, T.; Nishi, K.; Murakami, Y.; Watanabe, F.; Matsuura, T.; Wada, M.; Fujii, Y.; Yamada, M.; Ogawa, T.; Okada, T.; Hashizume, H.; Kii, M.; Hara, S.; Hagishita, S.; Nakamoto, S.; Yamada, K.; Chikazawa, Y.; Ueno, M.; Teshirogi, I.; Ono, T.; Ohtani, M. Pyrrolidine inhibitors of human cytosolic phospholipase A(2). J. Med. Chem., 2000, 43(6), 1041-1044.
Riendeau, D.; Guay, J.; Weech, P.K.; Laliberté, F.; Yergey, J.; Li, C.; Desmarais, S.; Perrier, H.; Liu, S.; Nicoll-Griffith, D. Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J. Biol. Chem., 1994, 269(22), 15619-15624.
Amandi-Burgermeister, E.; Tibes, U.; Kaiser, B.M.; Friebe, W.G.; Scheuer, W.V. Suppression of cytokine synthesis, integrin expression and chronic inflammation by inhibitors of cytosolic phospholipase A2. Eur. J. Pharmacol., 1997, 326(2-3), 237-250.
Burke, J.R.; Davern, L.B.; Stanley, P.L.; Gregor, K.R.; Banville, J.; Remillard, R.; Russell, J.W.; Brassil, P.J.; Witmer, M.R.; Johnson, G.; Tredup, J.A.; Tramposch, K.M. BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models. J. Pharmacol. Exp. Ther., 2001, 298(1), 376-385.
Roebrock, K.; Wolf, M.; Bovens, S.; Lehr, M.; Sunderkötter, C. Inhibition of benzalkonium chloride-induced skin inflammation in mice by an indol-1-ylpropan-2-one inhibitor of cytosolic phospholipase A2 α. Br. J. Dermatol., 2012, 166(2), 306-316.
Gewert, K.; Sundler, R. Dexamethasone down-regulates the 85 kDa phospholipase A2 in mouse macrophages and suppresses its activation. Biochem. J., 1995, 307(Pt 2), 499-504.
Lin, L.L.; Lin, A.Y.; DeWitt, D.L. Interleukin-1 alpha induces the accumulation of cytosolic phospholipase A2 and the release of prostaglandin E2 in human fibroblasts. J. Biol. Chem., 1992, 267(33), 23451-23454.
Anti-Inflammatory Drug Discovery; Levin, J. I., Laufer, S., Eds.; RSC drug discovery series; RSC Publ: Cambridge, 2012.
Gopalan, A.; Reuben, S.C.; Ahmed, S.; Darvesh, A.S.; Hohmann, J.; Bishayee, A. The health benefits of blackcurrants. Food Funct., 2012, 3(8), 795-809.
Arnold, E.; Benz, T.; Zapp, C.; Wink, M. Inhibition of cytosolic phospholipase A2α (cPLA2α) by medicinal plants in relation to their phenolic content. Molecules, 2015, 20(8), 15033-15048.
Baell, J.; Walters, M.A. Chemistry: Chemical con artists foil drug discovery. Nature, 2014, 513(7519), 481-483.
Baell, J.B. Screening-based translation of public research encounters painful problems. ACS Med. Chem. Lett., 2015, 6(3), 229-234.
Conde-Frieboes, K.; Reynolds, L.J.; Lio, Y-C.; Hale, M.R.; Wasserman, H.H.; Dennis, E.A. Activated ketones as inhibitors of intracellular Ca2+-dependent and Ca2+-independent phospholipase A2. J. Am. Chem. Soc., 1996, 118(24), 5519-5525.
Lehr, M.; Griessbach, K. Involvement of different protein kinases and phospholipases A2 in phorbol ester (TPA)-induced arachidonic acid liberation in bovine platelets. Mediators Inflamm., 2000, 9(1), 31-34.
Wang, H.; Klein, M.G.; Snell, G.; Lane, W.; Zou, H.; Levin, I.; Li, K.; Sang, B-C. Structure of human GIVD cytosolic phospholipase A2 reveals insights into substrate recognition. J. Mol. Biol., 2016, 428(13), 2769-2779.
Street, I. P.; Lin, H. K.; Laliberte, F.; Ghomashchi, F.; Wang, Z.; Perrier, H.; Tremblay, N. M.; Huang, Z.; Weech, P. K.; Gelb, M. H. Slow-and tight-binding inhibitors of the 85-kDa human phospholipase A2. Biochemistry [Mosc.], 1993, 32(23), 5935-5940.
Lucas, K.K.; Svensson, C.I.; Hua, X-Y.; Yaksh, T.L.; Dennis, E.A. Spinal phospholipase A2 in inflammatory hyperalgesia: role of group IVA cPLA2. Br. J. Pharmacol., 2005, 144(7), 940-952.
Kalyvas, A.; David, S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron, 2004, 41(3), 323-335.
Sanchez-Mejia, R.O.; Newman, J.W.; Toh, S.; Yu, G-Q.; Zhou, Y.; Halabisky, B.; Cissé, M.; Scearce-Levie, K.; Cheng, I.H.; Gan, L.; Palop, J.J.; Bonventre, J.V.; Mucke, L. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s disease. Nat. Neurosci., 2008, 11(11), 1311-1318.
Lio, Y.C.; Reynolds, L.J.; Balsinde, J.; Dennis, E.A. Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochim. Biophys. Acta, 1996, 1302(1), 55-60.
Leis, H.J.; Windischhofer, W. Inhibition of cyclooxygenases 1 and 2 by the phospholipase-blocker, arachidonyl trifluoromethyl ketone. Br. J. Pharmacol., 2008, 155(5), 731-737.
Deutsch, D.G.; Omeir, R.; Arreaza, G.; Salehani, D.; Prestwich, G.D.; Huang, Z.; Howlett, A. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol., 1997, 53(3), 255-260.
Omland, S.H.; Habicht, A.; Damsbo, P.; Wilms, J.; Johansen, B.; Gniadecki, R. A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. J. Eur. Acad. Dermatol. Venereol., 2017, 31(7), 1161-1167.
Lehr, M. 3-(Octadecanoylaminomethyl)indole-2-carboxylic acid derivatives and 1-methyl-3-octadecanoylindole-2-carboxylic acid as inhibitors of cytosolic phospholipase A2. Arch. Pharm. (Weinheim), 1996, 329(8-9), 386-392.
Lehr, M. Synthesis, biological evaluation, and structureactivity relationships of 3-acylindole-2-carboxylic acids as inhibitors of the cytosolic phospholipase A2. J. Med. Chem., 1997, 40(17), 2694-2705.
Lehr, M.; Klimt, M.; Elfringhoff, A.S. Novel 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A(2). Bioorg. Med. Chem. Lett., 2001, 11(19), 2569-2572.
Ghasemi, A.; Elfringhoff, A.S.; Lehr, M. Structure-activity relationship studies of 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A2α-mediated arachidonic acid release in intact platelets: variation of the keto moiety. J. Enzyme Inhib. Med. Chem., 2005, 20(5), 429-437.
McKew, J.C.; Lovering, F.; Clark, J.D.; Bemis, J.; Xiang, Y.; Shen, M.; Zhang, W.; Alvarez, J.C.; Joseph-McCarthy, D. Structure-activity relationships of indole cytosolic phospholipase A(2)α inhibitors: substrate mimetics. Bioorg. Med. Chem. Lett., 2003, 13(24), 4501-4504.
McKew, J.C.; Foley, M.A.; Thakker, P.; Behnke, M.L.; Lovering, F.E.; Sum, F-W.; Tam, S.; Wu, K.; Shen, M.W.H.; Zhang, W.; Gonzalez, M.; Liu, S.; Mahadevan, A.; Sard, H.; Khor, S.P.; Clark, J.D. Inhibition of cytosolic phospholipase A2α: hit to lead optimization. J. Med. Chem., 2006, 49(1), 135-158.
Lee, K.L.; Foley, M.A.; Chen, L.; Behnke, M.L.; Lovering, F.E.; Kirincich, S.J.; Wang, W.; Shim, J.; Tam, S.; Shen, M.W.H.; Khor, S.; Xu, X.; Goodwin, D.G.; Ramarao, M.K.; Nickerson-Nutter, C.; Donahue, F.; Ku, M.S.; Clark, J.D.; McKew, J.C. Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2α. J. Med. Chem., 2007, 50(6), 1380-1400.
McKew, J.C.; Lee, K.L.; Shen, M.W.H.; Thakker, P.; Foley, M.A.; Behnke, M.L.; Hu, B.; Sum, F-W.; Tam, S.; Hu, Y.; Chen, L.; Kirincich, S.J.; Michalak, R.; Thomason, J.; Ipek, M.; Wu, K.; Wooder, L.; Ramarao, M.K.; Murphy, E.A.; Goodwin, D.G.; Albert, L.; Xu, X.; Donahue, F.; Ku, M.S.; Keith, J.; Nickerson-Nutter, C.L.; Abraham, W.M.; Williams, C.; Hegen, M.; Clark, J.D. Indole Cytosolic Phospholipase A2 Alpha Inhibitors: Discovery and in Vitro and in Vivo Characterization of 4-{3-[5-Chloro-2-(2-{[(3,4-Dichlorobenzyl)sulfonyl)amino}ethyl)-1-(Diphenylmethyl)-1H-Indol-3-Yl)propyl}benzoic Acid, Efipladib. J. Med. Chem., 2008, 51(12), 3388-3413.
McKew, J.; Pong, K. Inhibitors of Cytosolic Phospholipase A2. US 20070004719 A1.
Chen, L.; Wang, W.; Lee, K.L.; Shen, M.W.H.; Murphy, E.A.; Zhang, W.; Xu, X.; Tam, S.; Nickerson-Nutter, C.; Goodwin, D.G.; Clark, J.D.; McKew, J.C. Reactions of functionalized sulfonamides: Application to lowering the lipophilicity of cytosolic phospholipase A2α inhibitors. J. Med. Chem., 2009, 52(4), 1156-1171.
Lamothe, J.; Lee, K.; Schelling, S.; Stedman, N.; Leach, M.; McKew, J.; Clark, J.; Nickerson-Nutter, C.; Sa Hegen, M. 29. Efficacy of Giripladib, a novel inhibitor of cytosolic phospholipase A2α, in two different mouse models of rheumatoid arthritis. Clin. Immunol., 2008, 127, S89-S90.
U.S. National Library of Medicine; Clinical trials: A study comparing 4 dose regimens of PLA-695, naproxen, and placebo in subjects with osteoarthritis of the knee. https://clinicaltrials.gov/ct2/show/NCT00396955?term=Giri pladib&rank=2 [Accessed December 28, 2007].
U.S. National Library of Medicine; Clinical trials: A study to determine the safety & efficacy of ZPL-5212372 in healthy subjects and in Subjects with atopic dermatitis. https://clinicaltrials.gov/ct2/show/NCT02795832?term=ZPL-5212372 [Accessed July 19, 2017].
Ludwig, J.; Bovens, S.; Brauch, C.; Elfringhoff, A.S.; Lehr, M. Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A2α. J. Med. Chem., 2006, 49(8), 2611-2620.
Drews, A.; Bovens, S.; Roebrock, K.; Sunderkötter, C.; Reinhardt, D.; Schäfers, M.; van der Velde, A.; Schulze Elfringhoff, A.; Fabian, J.; Lehr, M. 1-(5-carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A(2)α with reduced lipophilicity: synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity. J. Med. Chem., 2010, 53(14), 5165-5178.
Bovens, S.; Schulze Elfringhoff, A.; Kaptur, M.; Reinhardt, D.; Schäfers, M.; Lehr, M. 1-(5-Carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2α: effect of substituents in position 3 of the indole scaffold on inhibitory potency, metabolic stability, solubility, and bioavailability. J. Med. Chem., 2010, 53(23), 8298-8308.
Hess, M.; Schulze Elfringhoff, A.; Lehr, M. 1-(5-Carboxyand 5-carbamoylindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A2α: bioisosteric replacement of the carboxylic acid and carboxamide moiety. Bioorg. Med. Chem., 2007, 15(8), 2883-2891.
Fritsche, A.; Elfringhoff, A.S.; Fabian, J.; Lehr, M. 1-(2-Carboxyindol-5-yloxy)propan-2-ones as inhibitors of human cytosolic phospholipase A2α: synthesis, biological activity, metabolic stability, and solubility. Bioorg. Med. Chem., 2008, 16(7), 3489-3500.
Tomoo, T.; Nakatsuka, T.; Katayama, T.; Hayashi, Y.; Fujieda, Y.; Terakawa, M.; Nagahira, K. Design, synthesis, and biological evaluation of 3-(1-Aryl-1H-indol-5-yl)propanoic acids as new indole-based cytosolic phospholipase A2α inhibitors. J. Med. Chem., 2014, 57(17), 7244-7262.
Kokotou, M.G.; Limnios, D.; Nikolaou, A.; Psarra, A.; Kokotos, G. Inhibitors of phospholipase A2and their therapeutic potential: an update on patents (2012-2016). Expert Opin. Ther. Pat., 2017, 27(2), 217-225.
Kanai, S.; Ishihara, K.; Kawashita, E.; Tomoo, T.; Nagahira, K.; Hayashi, Y.; Akiba, S. ASB14780, an orally active inhibitor of group IVA phospholipase A2, is a pharmacotherapeutic candidate for nonalcoholic fatty liver disease. J. Pharmacol. Exp. Ther., 2016, 356(3), 604-614.
Arnsmann, M.; Hanekamp, W.; Elfringhoff, A.S.; Lehr, M. Structure-activity relationship studies on 1-(2-oxopropyl)indole-5-carboxylic acids acting as inhibitors of cytosolic phospholipase A2α: Effect of substituents at the indole 3-position on activity, solubility, and metabolic stability. Eur. J. Med. Chem., 2017, 125, 1107-1114.
Kirincich, S.J.; Xiang, J.; Green, N.; Tam, S.; Yang, H.Y.; Shim, J.; Shen, M.W.H.; Clark, J.D.; McKew, J.C. Benzhydrylquinazolinediones: novel cytosolic phospholipase A2α inhibitors with improved physicochemical properties. Bioorg. Med. Chem., 2009, 17(13), 4383-4405.
Mete, A.; Andrews, G.; Bernstein, M.; Connolly, S.; Hartopp, P.; Jackson, C.G.; Lewis, R.; Martin, I.; Murray, D.; Riley, R.; Robinson, D.H.; Smith, G.M.; Wells, E.; Withnall, W.J. Design of novel and potent cPLA2α inhibitors containing an α -methyl-2-ketothiazole as a metabolically stable serine trap. Bioorg. Med. Chem. Lett., 2011, 21(10), 3128-3133.
Walters, I.; Bennion, C.; Connolly, S.; Croshaw, P.J.; Hardy, K.; Hartopp, P.; Jackson, C.G.; King, S.J.; Lawrence, L.; Mete, A.; Murray, D.; Robinson, D.H.; Stein, L.; Wells, E.; John Withnall, W. Synthesis and evaluation of substrate-mimicking cytosolic phospholipase A2 inhibitors--reducing the lipophilicity of the arachidonyl chain isostere. Bioorg. Med. Chem. Lett., 2004, 14(14), 3645-3649.
Forster, L.; Ludwig, J.; Kaptur, M.; Bovens, S.; Elfringhoff, A.S.; Holtfrerich, A.; Lehr, M. 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)α and fatty acid amide hydrolase. Bioorg. Med. Chem., 2010, 18(2), 945-952.
Lehr, M. 3-(3,5-Dimethyl-4-octadecanoylpyrrol-2-yl)propionic acids as inhibitors of 85 kDa cytosolic phospholipase A2. Arch. Pharm. (Weinheim), 1996, 329(11), 483-488.
Lehr, M. Structure-activity relationships of (4-acylpyrrol-2-yl)alkanoic acids as inhibitors of the cytosolic phospholipase A2: variation of the substituents in positions 1, 3, and 5. J. Med. Chem., 1997, 40(21), 3381-3392.
Seno, K.; Okuno, T.; Nishi, K.; Murakami, Y.; Watanabe, F.; Matsuura, T.; Wada, M.; Fujii, Y.; Yamada, M.; Ogawa, T.; Okada, T.; Hashizume, H.; Kii, M.; Hara, S.; Hagishita, S.; Nakamoto, S.; Yamada, K.; Chikazawa, Y.; Ueno, M.; Teshirogi, I.; Ono, T.; Ohtani, M. Pyrrolidine inhibitors of human cytosolic phospholipase A(2). J. Med. Chem., 2000, 43(6), 1041-1044.
Ghomashchi, F.; Stewart, A.; Hefner, Y.; Ramanadham, S.; Turk, J.; Leslie, C.C.; Gelb, M.H. A pyrrolidine-based specific inhibitor of cytosolic phospholipase A(2)α blocks arachidonic acid release in a variety of mammalian cells. Biochim. Biophys. Acta, 2001, 1513(2), 160-166.
Seno, K.; Okuno, T.; Nishi, K.; Murakami, Y.; Yamada, K.; Nakamoto, S.; Ono, T. Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: Synthesis of potent and crystallized 4-triphenylmethylthio derivative ‘pyrrophenone’. Bioorg. Med. Chem. Lett., 2001, 11(4), 587-590.
Tai, N.; Kuwabara, K.; Kobayashi, M.; Yamada, K.; Ono, T.; Seno, K.; Gahara, Y.; Ishizaki, J.; Hori, Y. Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model. Inflamm. Res., 2010, 59(1), 53-62.
Burke, J.E.; Babakhani, A.; Gorfe, A.A.; Kokotos, G.; Li, S.; Woods, V.L., Jr; McCammon, J.A.; Dennis, E.A. Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry. J. Am. Chem. Soc., 2009, 131(23), 8083-8091.
Varghese, J.; Thorsett, E. Substituted Pyrimidine Compositions and Methods of Use. WO2000027824 A1.
Banville, J.; Balasubramanian, N. Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitors. US 20020065246 A1.
Kokotos, G.; Kotsovolou, S.; Six, D.A.; Constantinou-Kokotou, V.; Beltzner, C.C.; Dennis, E.A. Novel 2-oxoamide inhibitors of human group IVA phospholipase A(2). J. Med. Chem., 2002, 45(14), 2891-2893.
Kokotou, M.G.; Galiatsatou, G.; Magrioti, V.; Koutoulogenis, G.; Barbayianni, E.; Limnios, D.; Mouchlis, V.D.; Satpathy, B.; Navratil, A.; Dennis, E.A.; Kokotos, G. 2-Oxoesters: A novel class of potent and selective inhibitors of cytosolic group IVA phospholipase A2. Sci. Rep., 2017, 7(1), 7025. doi: 10.1038/s41598-017-07330-5.
Takagi, M.; Ishimitsu, K.; Nishibe, T. Oxa(thia)zolidine derivative and anti-inflammatory drug. U.S. Patent 6762200, July, 13, 2004.
Connolly, S.; Bennion, C.; Botterell, S.; Croshaw, P.J.; Hallam, C.; Hardy, K.; Hartopp, P.; Jackson, C.G.; King, S.J.; Lawrence, L.; Mete, A.; Murray, D.; Robinson, D.H.; Smith, G.M.; Stein, L.; Walters, I.; Wells, E.; Withnall, W.J. Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A(2) based on a 1,3-disubstituted propan-2-one skeleton. J. Med. Chem., 2002, 45(6), 1348-1362.
Payne, S.G.; Oskeritzian, C.A.; Griffiths, R.; Subramanian, P.; Barbour, S.E.; Chalfant, C.E.; Milstien, S.; Spiegel, S. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood, 2007, 109(3), 1077-1085.
Noha, S.M.; Jazzar, B.; Kuehnl, S.; Rollinger, J.M.; Stuppner, H.; Schaible, A.M.; Werz, O.; Wolber, G.; Schuster, D. Pharmacophore-based discovery of a novel cytosolic phospholipase A(2)α inhibitor. Bioorg. Med. Chem. Lett., 2012, 22(2), 1202-1207.
Makiyama, T.; Nagasaka, N.; Houjyo, Y.; Yamaura, E.; Nakamura, H.; Koide, Y.; Nishida, A.; Murayama, T. Newly synthetic ceramide-1-phosphate analogs; their uptake, intracellular localization, and roles as an inhibitor of cytosolic phospholipase A(2)α and inducer of cell toxicity. Biochem. Pharmacol., 2010, 80(9), 1396-1406.
Levy, R. Antisense Oligonucleotides Against Cpla2, Compositions And Uses Thereof. WO/2005/101968, 2005.
Solomonov, Y.; Hadad, N.; Levy, R. Reduction of cytosolic phospholipase A2α upregulation delays the onset of symptoms in SOD1G93A mouse model of amyotrophic lateral sclerosis. J. Neuroinflammation, 2016, 13(1), 134.
Hadad, N.; Burgazliev, O.; Elgazar-Carmon, V.; Solomonov, Y.; Wueest, S.; Item, F.; Konrad, D.; Rudich, A.; Levy, R. Induction of cytosolic phospholipase a2α is required for adipose neutrophil infiltration and hepatic insulin resistance early in the course of high-fat feeding. Diabetes, 2013, 62(9), 3053-3063.
Kim, D.H.; Fitzsimmons, B.; Hefferan, M.P.; Svensson, C.I.; Wancewicz, E.; Monia, B.P.; Hung, G.; Butler, M.; Marsala, M.; Hua, X-Y.; Yaksh, T.L. Inhibition of spinal cytosolic phospholipase A(2) expression by an antisense oligonucleotide attenuates tissue injury-induced hyperalgesia. Neuroscience, 2008, 154(3), 1077-1087.
Levy, R. Use of antisense oligonucleotides against CPLA2 in the treatment of cancer. WO2008038267A3. 2010.
Roshak, A.; Sathe, G.; Marshall, L.A. Suppression of monocyte 85-kDa phospholipase A2 by antisense and effects on endotoxin-induced prostaglandin biosynthesis. J. Biol. Chem., 1994, 269(42), 25999-26005.
Li, Q.; Cathcart, M.K. Selective inhibition of cytosolic phospholipase A2 in activated human monocytes. Regulation of superoxide anion production and low density lipoprotein oxidation. J. Biol. Chem., 1997, 272(4), 2404-2411.
Locati, M.; Lamorte, G.; Luini, W.; Introna, M.; Bernasconi, S.; Mantovani, A.; Sozzani, S. Inhibition of monocyte chemotaxis to C-C chemokines by antisense oligonucleotide for cytosolic phospholipase A2. J. Biol. Chem., 1996, 271(11), 6010-6016.